share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  11/22 16:38

Moomoo AI 已提取核心信息

On October 31, 2024, NeuroSense Therapeutics entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of up to $30 million in ordinary shares over 36 months. NeuroSense will not receive proceeds from the sale of shares by the Selling Shareholder but may receive up to $30 million from sales to YA under the agreement.The agreement includes the issuance of 224,697 Commitment Shares to YA as consideration. An additional 9,775,303 Advance Shares may be sold to YA at 97% of the lowest VWAP during a pricing period. The shares will be sold at NeuroSense's discretion, subject to market conditions and other factors.NeuroSense's ordinary shares are traded on Nasdaq under the symbol "NRSN". The company is an emerging growth company and a foreign private issuer, benefiting from reduced disclosure requirements. The proceeds will support the development of pipeline products and general corporate purposes.
On October 31, 2024, NeuroSense Therapeutics entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of up to $30 million in ordinary shares over 36 months. NeuroSense will not receive proceeds from the sale of shares by the Selling Shareholder but may receive up to $30 million from sales to YA under the agreement.The agreement includes the issuance of 224,697 Commitment Shares to YA as consideration. An additional 9,775,303 Advance Shares may be sold to YA at 97% of the lowest VWAP during a pricing period. The shares will be sold at NeuroSense's discretion, subject to market conditions and other factors.NeuroSense's ordinary shares are traded on Nasdaq under the symbol "NRSN". The company is an emerging growth company and a foreign private issuer, benefiting from reduced disclosure requirements. The proceeds will support the development of pipeline products and general corporate purposes.
2024年10月31日，NeuroSense Therapeutics与YA II PN，LTD.签署了一份备用权益购买协议，允许在36个月内最多出售3000万美元的普通股。NeuroSense将不会从股东融资计划出售股票中获得收益，但根据协议可能从向YA销售中获得多达3000万美元的收入。协议包括向YA发行224,697份承诺股作为交换。另外，9,775,303股预售股票可能以97%的最低成交量加权平均价出售给YA。股票将由NeuroSense自行决定出售，视市场条件和其他因素而定。NeuroSense的普通股在纳斯达克上以“NRSN”标的交易。该公司是一家新兴成长型公司且为外国私募发行人，受益于减少的披露要求。所得款项将用于支持管道产品的开发和一般企业用途。
2024年10月31日，NeuroSense Therapeutics与YA II PN，LTD.签署了一份备用权益购买协议，允许在36个月内最多出售3000万美元的普通股。NeuroSense将不会从股东融资计划出售股票中获得收益，但根据协议可能从向YA销售中获得多达3000万美元的收入。协议包括向YA发行224,697份承诺股作为交换。另外，9,775,303股预售股票可能以97%的最低成交量加权平均价出售给YA。股票将由NeuroSense自行决定出售，视市场条件和其他因素而定。NeuroSense的普通股在纳斯达克上以“NRSN”标的交易。该公司是一家新兴成长型公司且为外国私募发行人，受益于减少的披露要求。所得款项将用于支持管道产品的开发和一般企业用途。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间